ArticleClinical rheumatology2026
Subclinical atherosclerosis in patients with undifferentiated connective tissue disease: comparison with rheumatoid arthritis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the lipid profile and subclinical atherosclerosis in patients with undifferentiated connective tissue disease (UCTD), in comparison with rheumatoid arthritis (RA) and healthy individuals.
methodsThis cross-sectional controlled study included 30 patients with UCTD, treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), 59 patients with RA receiving csDMARDs, and 31 age- and sex-matched healthy controls. All participants had no history or presence of coronary artery disease, hypertension, diabetes mellitus, dyslipidemia, thyroid disease, smoking, and none received diuretics, cholesterol-lowering drugs, or other agents affecting the lipid profile. Fasting serum lipid parameters such as total cholesterol (TC), triglycerides (TGL), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured in all patients and controls. Subclinical atherosclerosis was assessed by measuring carotid intima-media thickness (cIMT) using ultrasonography.
resultsUCTD patients exhibited significantly lower TC and HDL-C levels compared with controls (204.4 ± 43.0 mg/dL vs 238 ± 41.4 mg/dL, p < 0.004 and 50.6 ± 9.5 mg/dL vs 61.3 ± 13.3 mg/dL, p < 0.002 respectively). They also presented with increased cIMT compared to healthy controls (0.8 [0.6-1.5] mm vs 0.6 [0.5-0.7] mm, p < 0.001). No differences were observed in TGL and LDL-C among UCTD and healthy controls. RA patients demonstrated higher cIMT (in unadjusted analyses) and HDL-C compared to UCTD patients (0.9 [0.8-1.0] mm vs 0.8 [0.6-1.5] mm, p < 0.001 and 56.8 ± 15.2 mg/dL vs 50.6 ± 9.5 mg/dL, p < 0.004 respectively). However, after multivariable linear regression analysis adjusting for age, sex, ESR, and disease duration, disease type was not independently associated with cIMT (β = 0.02, 95% CI - 0.16 to 0.19; p = 0.86).
conclusionsSubclinical atherosclerosis was observed in both RA and UCTD patients compared with healthy controls. Although RA patients exhibited higher cIMT values in unadjusted analyses, disease type was not independently associated with cIMT after multivariable adjustment. These findings suggest that cumulative inflammatory burden rather than diagnostic category alone may contribute to vascular alterations. Prospective longitudinal studies are required to clarify cardiovascular risk evolution in UCTD. Key Points • Patients with UCTD exhibit subclinical atherosclerosis despite conventional immunosuppressive treatment. • RA patients show a greater burden of subclinical atherosclerosis compared with UCTD patients in unadjusted analyses. • Quantitative lipid levels partly explain cardiovascular risk in inflammatory rheumatic diseases, highlighting the role of endothelial dysfunction and immune-mediated mechanisms.
Indexed as
Identifiers
41872662What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.